Probiotics lowered key inflammation markers in adults with depression

Chronic low-grade inflammation is widely acknowledged as one of the mechanisms underlying depression, which raises a practical question: can anything a person swallows over the counter actually shift that inflammatory state? Probiotics are an obvious candidate, because they act on the gut microbiome, and the microbiota-gut-brain axis is one of the routes through which the gut is thought to influence mood and immune signalling. Plenty of individual trials have tested probiotics in people with depression, but single small trials can point in different directions. Pooling them is the way to find out whether the inflammatory story holds up across the evidence as a whole.

The researchers ran a systematic sweep of the literature, searching PubMed and Google Scholar from inception to October 2025, and also screening Scopus, Embase, Web of Science and the Cochrane Library. They included only randomised controlled trials that tested probiotic supplementation against a comparator and measured circulating inflammatory biomarkers in adults diagnosed with depression. Ten trials met the criteria, covering 486 participants in total. The results were combined using random-effects models, which produce a pooled estimate of how much each blood marker moved with probiotics compared with control.

Probiotic supplementation was associated with a significant reduction in C-reactive protein, the most commonly used blood marker of inflammation, and a significant reduction in tumour necrosis factor-alpha. Interleukin-1 beta showed a borderline reduction, sitting right at the edge of statistical significance. Two other markers told a different story: interleukin-6 did not fall significantly, and interleukin-10, an anti-inflammatory signalling molecule, did not change either. So the picture is a partial one, with some inflammatory markers responding and others staying flat.

This analysis strengthens the biological plausibility of the gut-brain story in depression: if probiotics can genuinely dampen CRP and TNF-α in depressed adults, that gives the microbiome route to mood a measurable footing. But it also complicates the picture, because a true broad anti-inflammatory effect would be expected to move IL-6 as well, and it did not here. The pooled sample of 486 people across ten trials is modest, and the authors themselves note that larger and longer randomised trials are needed to confirm the effects and to work out which strains, doses and durations matter most.

If you follow the gut health conversation, this is a reason to take the anti-inflammatory case for probiotics a little more seriously in the context of depression, at least for some markers. It is equally a reason for restraint: the outcome here was blood chemistry, not how people felt, and a lower CRP reading is not the same thing as a lifted mood. Nothing in this analysis identifies which probiotic product produced the effect, so it cannot tell you whether the one on the shop shelf would do the same. Treat it as an interesting signal about the gut-brain connection rather than a settled result.